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Abstract: Chronic hyperglycaemia is a major risk factor for diabetes-induced cardiovascular
dysfunction. In a hyperglycaemic state, excess production of reactive oxygen species (ROS), coupled
with decreased levels of glutathione, contribute to increased lipid peroxidation and subsequent
myocardial apoptosis. N-acetylcysteine (NAC) is a thiol-containing antioxidant known to protect
against hyperglycaemic-induced oxidative stress by promoting the production of glutathione. While
the role of NAC against oxidative stress-related cardiac dysfunction has been documented, to date
data is lacking on its beneficial effect when used with glucose lowering therapies, such as metformin
(MET). Thus, the aim of the study was to better understand the cardioprotective effect of NAC plus
MET against hyperglycaemia-induced cardiac damage in an H9c2 cardiomyoblast model. H9c2
cardiomyoblasts were exposed to chronic high glucose concentrations for 24 h. Thereafter, cells were
treated with MET, NAC or a combination of MET and NAC for an additional 24 h. The combination
treatment mitigated high glucose-induced oxidative stress by improving metabolic activity i.e. ATP
activity, glucose uptake (GU) and reducing lipid accumulation. The combination treatment was as
effective as MET in diminishing oxidative stress, lipid peroxidation and apoptosis. We observed
that the combination treatment prevented hyperglycaemic-induced cardiac damage by increasing
GLUT4 expression and mitigating lipid accumulation via phosphorylation of both AMPK and AKT,
while decreasing nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), as well as
protein kinase C (PKC), a known activator of insulin receptor substrate-1 (IRS-1), via phosphorylation
at Ser307. On this basis, the current results support the notion that the combination of NAC and
MET can shield the diabetic heart against impaired glucose utilization and therefore its long-term
protective effect warrants further investigation.
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1. Introduction
According to the latest IDF report (2017), the global prevalence of diabetes is rising all over the
world [1]. This rising diabetes epidemic contributes significantly to the aetiology of cardiovascular
dysfunction, with diabetic individuals presenting increasingly with heart failure (HF) [2]. A large body
of evidence suggests that chronic hyperglycaemia, linked to augmented reactive oxygen species (ROS)
levels and oxidative stress, plays a major role in the development and progression of deteriorated
cardiac function [3–6]. For example, in the diabetic heart, aberrant glucose auto-oxidation and shifts in
redox balance are known to decrease tissue concentration of glutathione (GSH) and impair antioxidant
defence enzymes, such as superoxide dismutase (SOD) and catalase (CAT) [5,7]. Consequently,
large amounts of mitochondrial ROS are produced that promote the degeneration of biological
macromolecules, propagating lipid peroxidation while decreasing metabolic activity. Furthermore, in
the failing heart free fatty acids become the preferred energy substrate, resulting in increased formation
of diacylglycerol (DAG) [5,8]. Diacylglycerol, in turn, activates nuclear factor-kappa B (NF-kB) and
protein kinase C (PKC) which later blunts peripheral glucose uptake (GU) by phosphorylating insulin
receptor substrate 1 (IRS-1) at Ser307 and prevents insulin-mediated phosphorylation of protein kinase
B (AKT)Thr473, while diminishing glucose transporter (GLUT) 4 uptake from peripheral tissue [9].
Altogether, cytosolic adenosine triphosphate (ATP) production is diminished, which furthermore
exacerbates mitochondrial depolarization and increases the release of cytochrome C, caspase 3/7 activity
and subsequent cardiac apoptosis. At present, commonly used antidiabetic drugs such as metformin
are known to present limited efficacy in protecting against the aforementioned diabetes associated
cardiac complications.
Metformin is an insulin sensitizing agent known to partially protect the heart from high glucose
induced oxidative stress [10]. However, as a result of the continuous increase in deaths of diabetic
patients, it is presumed the long-term effect of MET to protect the diabetic myocardium diminishes
over time. For this reason, supplementation of glucose lowering drugs with natural antioxidants
is increasingly being explored to improve cardiac health. Various studies have focused on the use
of N-acetylcysteine (NAC) to reduce oxidative stress, as recently reviewed [11]. In the later review,
scientific evidence is provided confirming that NAC is a potent antioxidant and, as a precursor of GSH,
has attracted great interest as a ROS scavenger [11,12]. NAC has been shown to improve atrial fibrillation
(AF), decrease ischaemic reperfusion injury and potentiate the effect of angiotensin-converting enzymes
in myocardial infarction episodes [13,14]. Furthermore, treatment with NAC is known to improve
cardiac remodelling by decreasing ROS-mediated NF-kB-activation, which contributes to decreased
GU, mitochondrial dysfunction and subsequent apoptosis of the stressed myocardium [15]. However,
to date, limited studies are available on the ability of NAC to decrease intracellular oxidative stress
when used in combination with the glucose lowering drug MET. Thus, this study aims to investigate
the protective effect for the combined use of NAC and MET, as well as the mechanism employed to
improve GU in an in vitro H9c2 cardiomyoblast model.
2. Materials and Methods
2.1. Metformin and N-Acetylcysteine Preparation
A 10 mM stock solution of both MET and NAC (both supplied by Sigma-Aldrich, Saint Louis,
MO, USA) was made in tissue culture (TC) grade water (Lonza, Walkersville, MD, USA) and thereafter,
2 mM working stock solutions were prepared and filter-sterilised. Final concentrations of 1 µM MET
and/or 1 mM NAC were prepared in Dulbecco’s Modified Eagle Medium (DMEM) (supplemented
with 1% v/v foetal bovine serum (FBS)) and containing 33 mM glucose (Lonza BioWhittaker, Verviers,
Belgium) for subsequent experimental analysis.
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2.2. Effect of MET and NAC on H9c2 Cells Exposed to High Glucose
Rat heart derived ventricular H9c2 (ATCC, CRL-1446) cardiomyoblasts, obtained from the
American Type Culture Collection, are immortalized cells with a cardiac phenotype. The H9c2
cells are extensively used to study cardiovascular dysfunction caused by prolonged high glucose
exposure [16,17]. Briefly, H9c2 cells were cultured in DMEM (supplemented with 10% v/v FBS) under
standard tissue culture conditions (37 ◦C in humidified air and 5% CO2) in a 75 cm2 flask and media
was refreshed every two days. Upon 80% confluency, cells were split and seeded in DMEM for 48
h in either a 6-well plate (2 × 105 cells/well) for protein, 96-well plate (0.8 × 105 cells/well) for ATP
or 24-well plate (1 × 105 cells/well) for all other analyses. Subsequently, H9c2 cells were cultured
in glucose-free DMEM without phenol red (Sigma-Aldrich, Saint Louis, MO, USA), supplemented
with 1% bovine serum albumin (BSA) for 30 min, before hyperglycaemia was induced by exposing
H9c2 cardiomyoblasts to 33 mM glucose (high glucose; HG) for 24 h, as per the method described
by Jadaun et al. [16]. The following day, to assess the ability of NAC plus MET to attenuate high
glucose-induced cardiac injury, H9c2 cardiomyoblasts were treated with either 1 mM NAC, 1 µM MET
or a combination of NAC plus MET for 24 h. Cells exposed to either normal glucose (NG; 5.5 mM) or
HG were treated with the vehicle control. All treatment doses were based on results obtained from
previous studies [4,7,18–21].
2.3. Measurement of Metabolic Activity
The ViaLight™ plus Adenosine Triphosphate (ATP) kit (Lonza, Basel, Switzerland), was used
as a rapid screening method to measure metabolic activity and cytotoxicity, as per manufacturer’s
instructions. Briefly, cells cultured in white 96-well plates were removed from the incubator after the
predetermined treatment conditions. Next, 50 µL of the culture media remained and 50 µL of the cell
lysis buffer, provided in the kit, was added to each well and incubated for 10 min at room temperature.
Thereafter, 100 µL of AMR plus solution was added to each well and incubated for an additional 2 min.
Luminescence was quantified using the BioTek FL×800 plate reader and analysed with the Gen 5
software (Bio-Tek Instruments Inc., Winooski, VT, USA).
2.4. Measurement of 2-Deoxy-[3H]-D-Glucose (DOG) Uptake
Radiolabelled 2-Deoxy-[3H]-D-glucose (DOG) uptake was measured in H9c2 cells to assess
myocardial glucose uptake. The principle behind the assay entails the addition of radioactively labelled
DOG to H9c2 cardiomyoblasts, followed by quantifying DOG by means of a scintillation counter. To
assess NAC and MET ability to improve GU in H9c2 cardiomyoblasts after high glucose exposure, DOG
uptake was performed as per the previously published protocol [7]. Briefly, after the predetermined
treatment, H9c2 cells were exposed to 0.5 µCi/mL 3H-2-DOG and 2% BSA for 15 min in a 24-well tissue
culture plates. Thereafter, cells were lysed with 0.1 M NaOH/1% SDS and incubated for an additional
45 min at 37 ◦C. An aliquot was used for protein determination and the remaining cell lysates were
then added to scintillation vials containing 1 mL tissue culture (TC) grade water. Subsequently, 8 mL
of Ready Gel Ultima Gold was pipetted into scintillation vials and equilibrated overnight at room
temperature, where after DOG was assessed in a liquid scintillation analyser (2200 CA, Parkard Tricarb
series) by liquid scintillation (PerkinElmer, Downers, Crove, IL, USA). Results obtained were then
calculated as previously described and expressed in arbitrary units [7].
2.5. Quantification of Intracellular Lipid Content
Cardiac lipid accumulation is associated with decreased cardiac function. To quantify lipid
accumulation, Oil red O (ORO) staining (Sigma-Aldrich, St Louis, MO, USA), a widely used lysochrome
(fat-soluble) diazo dye for staining and quantifying neutral intracellular lipids, was adapted as
previously described [22]. Briefly, following the relevant treatment conditions, H9c2 cells were fixed
with 4% (v/v) paraformaldehyde for 15 min and washed three times in PBS. Thereafter, cells were
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incubated in freshly prepared 0.7% (v/v) ORO staining solution for 30 min at room temperature.
Following a 5 min rinse in distilled water, cells were immersed in 100% isopropanol for 20–30 s to
extract the dye. Supernatants were then transferred to a 96-well plate for measurement of optical
density for lipid accumulation at 490 nm with a BioTek EL×800 plate reader using Gen 5 software.
For normalisation, cells were treated with 70% ethanol, then the solution was aspirated before the
addition of 400 µL crystal violet (CV) for 5 min at room temperature. The CV was removed, and cells
washed with PBS. Thereafter, 70% ethanol was added to extract the CV and 100 µL transferred to a
clean 96-well plate for the measurement of optical density at 570 nm.
2.6. Measurement of Intracellular Reactive Oxygen Species (ROS)
Intracellular production of ROS was detected using 2’,7’-dichlorflourescein diacetate (DCFH-DA)
fluorescent dye (Cell Biolabs Inc., San Diego, CA, USA), as per the previously described protocol [7].
Briefly, intracellular production of ROS was evaluated after H9c2 cells were exposed to 100 µL of
1 µM DCFH-DA. Thereafter the cells were incubated under standard TC conditions for 30 min. Next,
HBSS was added and the DCFH-DA fluorescent intensity was measured at an excitation and emission
wavelength of 485 ± 20 nm/ 528 ± 20 nm by means of a BioTek FL×800 plate reader and analysed using
Gen 5® software.
2.7. Measurements of Superoxide Dismutase (SOD) Activity
Superoxide dismutase (SOD) is an endogenous antioxidant which scavenges the superoxide
anion into hydrogen peroxide and oxygen. SOD activity was measured by means of a Biovision
SOD activity kit (Mountain View, CA, USA), according to manufacturer’s instructions. Briefly, H9c2
cardiomyoblasts were lysed by the addition of 100 µL of 0.1 M trizma/hydrochloride (Tris/HCl) and
0.1 mg/mL phenylmethylsulfonyl fluoride (PMSF). Lysed cells were then centrifuged at 15,000× g for
5 min at 4 ◦C. Twenty microliter of the cell lysates were then transferred to a fresh 96-well plate with
the addition of 200 µL WST and 20 µL Enzyme Working Solution (supplied in the kit), where after the
cells were incubated at 37 ◦C for 20 min prior to measuring of SOD activity. Absorbance was read at an
excitation and emission wavelength of 485 ± 20 nm/528 ± 20 nm with a Biotek ELX 800 plate reader
using Gen 5 software.
2.8. Measurements of Glutathione (GSH) Content
The Glutathione Luminescent-based assay is an assay design for the quantification and detection
of glutathione (GSH) levels, a known antioxidant. Total glutathione content was assessed using a
7-amino-4-chloromethylcoumarin CellTrackerTM Blue dye (Invitrogen Corporation, Carlsbad, CA,
USA) assay kit following the manufacturer’s guidelines. Briefly, cells cultured in white 96-well TC
plates, were lysed in 50 µL GSH lysis reagent. Cells were mixed using a orbital shaker for 5 min, where
after 50 µL of a luciferin generation reagent was added and cells incubated for an additional 15 min at
room temperature. GSH fluorescent intensity was determined using the BioTek FL×800 plate reader
with an excitation at 485 ± 20 nm and emission at 528 ± 20 nm.
2.9. Lipid Peroxidation Analysis
The thiobarbituric acid reactive substances (TBARS) assay is an established method that quantifies
lipid peroxides based on the production of a reactive aldehyde, malondialdehyde (MDA). Lipid
peroxidation was assessed by using an OxiSelect™ TBARS assay kit, as previously described [7,23].
Briefly, H9c2 cells were scraped using a rubber policeman and resuspended in 1 mL DPBS containing
10 µL of butylated hydroxytoluene, before being homogenized for 1 min. Thereafter, 100 µL of sodium
dodecyl sulfate lysis solution was pipetted into new eppendorfs containing 100 µL of standards and
the treated samples (H9c2 cell lysate). The sample mixtures were vortexed and incubated for 5 min at
room temperature. Subsequently, 250 µL of thiobarbituric acid reagent was pipetted into each tube,
thoroughly mixed and incubated for 45–60 min at 95 ◦C before centrifuging for 15 min at 1500× g.
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Next, supernatants of samples and standards were inserted into a new 96-well plate to measure the
absorbance at 532 nm using a BioTek ELX800 plate reader (Gen 5 software).
2.10. Evaluating Mitochondrial Membrane Potential (∆Ψm)
JC-1 stain was used to assess mitochondrial membrane depolarization, as previously
described [7,23]. Briefly, treated H9c2 cardiomyocytes were washed with warm DPBS before staining
with 2 µM JC-1 solution in DMEM without phenol red, and then incubated at standard tissue culture
conditions for 30 min in the dark. Thereafter, cardiomyocytes were washed with warm DPBS and
the fluorescence was measured at Excitation of 485 ± 20 nm and dual Emission of 530 ± 25 nm and
590 ± 35 nm, using a BioTek FL×800 plate reader (BioTek Instruments Inc., Winooski, VT, USA) and
fluorescence quantified using Gen 5 software.
2.11. The Activity of Caspase 3/7
Caspase 3/7 activity was determined as per previously described protocol [7]. Briefly, treated
cells were lysed and 20 µL of cell lysates were transferred to a 96-well plate and mixed with 20 µL
of Caspase-Glo reagent (Promega, Madison, WI, USA) before the reaction was incubated for 30 min
in the dark. A BioTek FLX 800 plate reader with Gen 5 software was used to measure luminescence.
Data were normalised to previously acquired protein content using the reducing agent and detergent
compatible (RC DC™) protein assay (Bio-Rad, Hercules, CA, USA).
2.12. Western Blot Analysis
Protein expression was determined by Western blot analysis as previously described [7]. Briefly,
40 µg of protein lysate was denatured and loaded onto a 10% SDS-polyacrylamide gel and transferred
to a polyvinylidene fluoride membrane. Nonspecific binding on the membranes was blocked using
5% w/v low-fat milk in Tris-buffered saline with Tween-20. Subsequently, the membrane was
incubated overnight at 4 ◦C with the relevant Cell Signaling (Beverly, MA, USA) primary antibodies:
Phosphorylated Protein kinase B at Ser 473 (p-AKTSer473; 1:1000), phosphorylated 5’ AMP-activated
protein kinase at threonine 174 (p-AMPKThr174; 1:800), phosphorylated nuclear factor-kappa β
phosphorylation at serine 536 (p-NF-kBSer536, 1:1000), phosphorylated Insulin receptor substrate-1
phosphorylation at serine 307 (p-IRS-1Ser307, 1:1000), protein kinase C phosphorylation at serine
660 (p-PKCSer660, 1:1000) and GLUT4 (1:800) (Sigma-Aldrich, Saint Louis, MO, USA). The relevant
horseradish peroxidase-conjugated secondary antibodies were applied the following day for 90 min
at room temperature. β-Actin (1:2000) (Santa Cruz Biotechnology, Dallas, TX, USA) antibody was
added as a loading control. Proteins were detected and quantified using a Chemidoc-XRS imager and
Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA).
3. Results
3.1. The Combination Effect of MET and NAC on ATP Activity
ATP, as a measurement of cellular metabolic activity, was used to assess the effect of high glucose
(HG; 33 mM) on H9c2 cardiomyoblasts over a period of 24 h. Cells cultured in HG displayed a
significant decrease in ATP activity compared to the normal glucose (NG; 5.5 mM) control (46% vs.
100%; p < 0.001). Treatment with either NAC (77% vs. 46%; p < 0.05), MET (118% vs. 46%; p < 0.001)
or MET+NAC (128% vs. 46%; p < 0.001) was able to significantly improve the metabolic activity of
cardiomyoblasts exposed to HG. The combination of MET+NAC was as effective as the MET treatment
and more effective than NAC alone (128% vs. 77%; p < 0.05) (Figure 1).
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Figure 1. The combination effect of Metformin (MET) and N-acetylcysteine (NAC) on high glucose-
induced metabolic activity. H9c2 cardiomyoblasts were cultured in high glucose (HG; 33 mM) for 24 
h. Thereafter, cardiomyoblasts were treated with NAC (1 mM), metformin (MET) (1 µM) and a 
combination of MET+NAC. Cells treated with normal glucose (NG) served as the vehicle control. Data 
are presented as the mean ± SEM of 3 distinct biological experiments with each experiment having 3 
technical repeats (n = 9). Significance is depicted as *** p ≤ 0.001 versus NG control, # p < 0.05, ### p ≤ 
0.001 versus HG control and † p < 0.05 versus NAC only. 
3.2. The Combination Effect of MET and NAC on Glucose Uptake (GU) 
Impaired cardiac glucose regulation is closely linked with the development of HF. Glucose 
uptake was measured in H9c2 cardiomyoblasts exposed to HG levels and treated with or without 
NAC, MET and MET+NAC. As anticipated, GU was decreased in H9c2 cells exposed to HG when 
compared to the NG control (83%; p < 0.01). No significant difference was observed in cells exposed 
to NAC in comparison to the HG control. Interestingly, enhanced GU was displayed by cells treated 
with the combination of MET+NAC when compared to the HG control (116%, p < 0.05) as well as the 
cells treated with MET alone (46%, p < 0.05) (Figure 2). The combination of MET+NAC was better 
than NAC alone. 
Figure 1. The combination effect of Metformin (MET) and N-acetylcysteine (NAC) on high
glucose-induced metabolic activity. H9c2 cardiomyoblasts were cultured i high glucose (HG; 33 mM)
for 24 h. Thereafter, cardiomyoblasts were treated ith NAC (1 mM), metformin (MET) (1 µM) and a
combination of MET+NAC. Cells treated with normal glucose (NG) served as the vehicle control. Data
are presented as the mean ± SEM of 3 distinct biological experiments with each experiment having
3 technical repeats (n = 9). Significance is depicted s *** p ≤ 0.001 versus NG control, # p < 0.05,
### p ≤ 0.001 versus HG control and † p < 0.05 versus NAC only.
3.2. The Combination Effect of MET and NAC on Glucose Uptake (GU)
Impaired cardiac glucose regulation is closely linked with the development of HF. Glucose uptake
was measured in H9c2 cardiomyoblasts exposed to HG levels and treated with or without NAC, MET
and MET+NAC. As anticipated, GU was decreased in H9c2 cells exposed to HG when compared to
the NG control (83%; p < 0.01). No significant difference was observed in cells exposed to NAC in
co parison to the HG control. Interestingly, enhanced GU was displayed by cells treated with the
combination of MET+NAC when compared to the HG control (116%, p < 0.05) as well as the cells
treated with MET alone (46%, p < 0.05) (Figure 2). The combination of MET+NAC was better than
NAC alone.
3.3. The Combination Effect of MET and NAC on Lipid Content
Increase in cellular lipid accumulation can lead to cardiac dysfunction. H9c2 cardiomyoblasts
exposed to HG displayed a significant increase in lipid content in comparison to the NG control
(91% increase p < 0.001). Treatment with either NAC, MET or the combination of MET+NAC was able
to decrease lipid accumulation when compared to the HG control (decrease by 56% and 66% and 64%;
p < 0.001). MET+NAC treatment was as effective at reducing lipid content as treatment with MET only
(Figure 3).
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Figure 2. The combination effect of Metformin (MET) and N-acetylcysteine (NAC) on high
glucose-induced H9c2 cells glu ose uptake. H9c2 cardiomyoblasts were cultured in hig glucose (HG;
33 mM) for 4 h. Cardi myoblasts were then co-treated with NAC (1 mM), metformin MET) (1 µM)
and a combination f MET+NAC. Cells treated with normal glucose (NG) served as the vehicle co trol.
Data are presented as the mean ± SEM of 3 distinct biological experiments with each exp riment having
3 technical repeats (n = 9). Significance is depicted as ** p ≤ 0.01 ver us NG control, # p < 0.05 ersus
HG control † p < 0.05 versus NAC only.
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3.4. The Combination Effect of MET and NAC to Attenuate ROS Production 
High glucose-stimulated oxidative stress is related to accelerated cardiovascular disease. H9c2 
cardiomyoblasts, cultured in HG, exhibited a significant increase in intracellular ROS levels in 
comparison to the NG control (152% vs. 100%; p < 0.001). Treatment with either NAC (104%; p < 0.01) 
or MET (95%; p < 0.001) or the combination MET+NAC (97%; p < 0.001) drastically decreased the 
production of intracellular ROS when compared to the HG control (Figure 4). The combined use of 
MET+NAC was as effective as the MET treatment alone. 
Figure 3. The combination effect of Metformin (MET) and N-acetylcysteine (NAC) to reverse high
glucose-induced lipid accumulation. H9c2 cardiomyoblasts were cultured in high glucose (HG; 33 mM)
for 24 h. Cells were then co-treated with NAC (1 M), metformin (MET) (1 µM) and a combinatory
treatment of MET+NAC. Cells treated with normal glucose (NG) served as the vehicle control. Results
are expressed as the mean ± SEM of 3 independent biological experiments with each experiment having
3 technical replicat s (n = 9). Significance is depicted as *** p ≤ 0.001 versus NG control, ### p ≤ 0.001
versus HG control.
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3.4. The Combination Effect of MET and NAC to Attenuate ROS Production
High glucose-stimulated oxidative stress is related to accelerated cardiovascular disease. H9c2
cardiomyoblasts, cultured in HG, exhibited a significant increase in intracellular ROS levels in
comparison to the NG control (152% vs. 100%; p < 0.001). Treatment with either NAC (104%; p < 0.01)
or MET (95%; p < 0.001) or the combination MET+NAC (97%; p < 0.001) drastically decreased the
production of intracellular ROS when compared to the HG control (Figure 4). The combined use of
MET+NAC was as effective as the MET treatment alone.
Nutrients 2019, 11, x FOR PEER REVIEW 9 of 20 
 
 
Figure 4. The combination effect of Metformin (MET) and N-acetylcysteine (NAC) on high glucose-
induced oxidative stress. 2’, 7’-Dichlorofluorescin diacetate (DCFH-DA) fluorescence as a 
measurement of reactive oxygen species production was assessed in H9c2 cardiomyoblasts cultured 
in high glucose (HG; 33 mM) for 24 h. Cells co-treated with NAC (1 mM), metformin (MET) (1 µM) 
and a combination of MET+NAC attenuated this effect. Cells treated with normal glucose (NG) served 
as the vehicle control. Data are expressed as the mean ± SEM of 3 independent experiments with each 
experiment having 3 technical repeats (n = 9). Significance is depicted as *** p ≤ 0.001 versus NG 
control, ## p ≤ 0.01, ### p ≤ 0.001 versus HG control. 
3.5. The Combination Effect of MET and NAC to Diminish Lipid Peroxidation 
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(45% increase; p < 0.001). The combination of MET+NAC (18% decease; p < 0.05) was able to decrease 
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Figure 4. The combination effect of Metformin (MET) and N-acetylcysteine (NAC) on high
glucose-induced oxidative stress. 2’, 7’-Dichlorofluorescin diacetate (DCFH-DA) fluorescence as
a measurement of reactive oxygen species production was assessed in H9c2 cardiomyoblasts cultured
in high glucose (HG; 33 mM) for 24 h. Cells co-treated with NAC (1 mM), metformin (MET) (1 µM)
and a combination of MET+NAC attenuated this effect. Cells treated with normal glucose (NG) served
as the vehicle control. Data are expressed as the mean ± SEM of 3 independent experiments with each
experiment having 3 technical repeats (n = 9). Significance is depicted as *** p ≤ 0.001 versus NG
control, ## p ≤ 0.01, ### p ≤ 0.001 versus HG control.
3.5. The Combination Effect of MET and NAC to Diminish Lipid Peroxidation
Hyperglycaemia and oxidative stress play a crucial role in the ysregulation of lipid peroxidation
(malondialdehyde-MDA) in the diabetic heart. High glucose-induced lipid peroxidation was evident
in H9c2 cardiomyoblasts exposed to HG when compared to the NG control (45% increase; p < 0.001).
The combination of MET+NAC (18% decease; p < 0.05) was able to decrease the production of MDA to
a similar effect as either NAC (25% decrease; p < 0.05) or MET (23% decrease; p < 0.05) when compared
the HG control (Figure 5). However, the treatments did not reverse lipid peroxidation to the level of
the NG control.
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technical repeats (n = 9). Significance is depicted as *** p ≤ 0.001 versus NG control, # p < 0.05, versus 
HG control. 
3.6. The Combination Effect of MET and NAC to Augment SOD Activity And GSH Content 
Increased oxidative stress is the main initiator of cardiac dysfunction in the diabetic heart. This 
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peroxi at on. H9c2 cardiomyobl sts were cultured in high glucose (HG; 33 M) for 24 h. Cells were
then co- reated with NAC (1 mM), metformin (MET) (1 µM) and a combination of MET+NAC. Data
are presented as the mean ± SE of 3 distinct biological experiments with each experiment having 3
technical r pe ts (n = 9). Significance is depicted as *** p ≤ 0.001 ver us NG control, # p < 0.05, versus
HG control.
3.6. The Combination Effect of MET and NAC to Augment SOD Activity And GSH Content
Increased oxidative stress is the main initiator of cardiac dysfunction in the diabetic heart. This
study showed that H9c2 cardiomyoblasts cultured in HG displayed a significant reduction in SOD
activity (31% compared to 100% p < 0.001) and GSH content (83% compared to 100%; p < 0.01)
when compared to the normal control. This effect was abolished when cells were treated with NAC
(p < 0.001), MET (p < 0.001) and the combination of MET+NAC (p < 0.001); (Figure 6A,B). Treatment
with the combination of MET+NAC significantly increased SOD activity when compared to either
NAC (p < 0.05) or MET (p < 0.01) alone.
3.7. The Combination Effect of MET and NAC to Modify Mitochondrial Membrane Potential (∆Ψm)
Impaired mitochondrial potential as a measurement of early apoptosis was assessed in
cardiomyoblasts cultured in HG. There was a significant increase in depolarised mitochondria
in cells exposed to HG when compared to the NG control (2.8 compared to 1.3, p < 0.001). Treatment
with MET (1.39; p < 0.001) significantly prevented mitochondrial depolarisation, whereas NAC as well
as the combination of MET+NAC only showed a trend towards decreased depolarisation (p < 0.05,
Figure 7).
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Figure 7. The combination effect of Metformin (MET) and N-acetylcysteine (NAC) on mitochondrial
potential. H9 2 cardiomyoblasts were cultured in high glucose (HG; 33 mM) for 24 h. Thereafter, cells
were treated with NAC (1 mM), m tformin (MET) (1 µM) and a combinati n of MET+NAC. Cells
treated with normal glucose (NG) served as the vehicle control. Data are presented as the mean ±
SEM of 3 separate biological experiments with each experiment having 3 technical repeats (n = 9).
Significance is depicted as *** p ≤ 0.001 versus NG control, ### p ≤ 0.001 versus HG control and
‡‡‡ p ≤ 001 compared to MET.
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3.8. The Effect of MET and NAC on DNA Fragmentation
TUNEL assay was used for the detection of DNA fragmentation, which is a hallmark of apoptosis.
In this study, increased TUNEL positive cells were detected in cardiomyoblasts exposed to HG when
compared to the NG control (13.63 ± 1.96 compared to 1.75 ± 0.77; p < 0.001). Metformin treatment
significantly (6.50 ± 1.99; p < 0.05) decreased this effect to a similar degree in cells exposed to the
combination treatment of MET+NAC (6.25 ± 1.42; p < 0.05), whereas NAC treatment showed a
trend towards reduced activity when compared to the HG control (10.63 ± 1.96 versus 102.63 ± 1.39).
MET+NAC was able to reduce DNA fragmentation to a similar degree as the MET treatment (Figure 8),
but none of the treatments reduced DNA fragmentation to the levels of the NG control.




Figure 8. The combination effect of Metformin (MET) and N-acetylcysteine (NAC) on high glucose-
induced DNA fragmentation. (A) Photograph microscopy analysis of Tunel positive cells as observed 
with green fluorescence. (B) Bar graph analysis. H9c2 cardiomyoblasts were cultured in high glucose 
(HG; 33 mM) for 24 h. Cells were then treated with NAC (1 mM), metformin (MET) (1 µM) and a 
combination of MET+NAC. Cells treated with normal glucose (NG) served as the vehicle control. Data 
presented are expressed as the mean ± SEM of 3 separate biological experiments with each experiment 
having 3 technical repeats (n = 9). Significance is depicted as *** p ≤ 0.001 versus NG control, # p < 0.05 
## p ≤ 0.01 versus HG control. 
3.9. The Effect of MET and NAC on Caspase 3/7 Activity 
Caspase 3/7 activity assay is used to measure cellular apoptotic death. High glucose treatment 
significantly increased caspase-3/7 activity in H9c2 cardiomyoblasts when compared to the NG 
control (p < 0.001). Treatment with MET+NAC (p < 0.01), MET (p < 0.01) as well as NAC (p < 0.01), was 
able to decrease caspase activity, however the treatments were unable to completely reduce caspace 
3/7 activity to the level of the NG control (Figure 9). 
Figure 8. The combination effect of Metformin (MET) and N-acetylcysteine (NAC) on high
glucose-induced DNA fragmentation. (A) Photograph microscopy analysis of Tunel positive cells as
observed with green fluorescence. (B) Bar graph analysis. H9c2 cardiomyoblasts were cultured in
high glucose (HG; 33 mM) for 24 h. Cells were then treated with NAC (1 mM), metformin (MET)
(1 µM) and a combination of MET+NAC. Cells treated with normal glucose (NG) served as the vehicle
control. Data presented are expressed as the mean ± SEM of 3 separate biological experiments with
each experiment having 3 technical repeats (n = 9). Significance is depicted as *** p ≤ 0.001 versus NG
control, # p < 0.05.
3.9. The Effect of MET and NAC on Caspase 3/7 Activity
Caspase 3/7 activity assay is used to measure cellular apoptotic death. High glucose treatment
significantly increased caspase-3/7 activity in H9c2 cardiomyoblasts when compared to the NG control
(p < 0.001). Treatment with MET+NAC (p < 0.01), MET (p < 0.01) as well as NAC (p < 0.01), was able
to decrease caspase activity, however the treatments were unable to completely reduce caspace 3/7
activity to the level of the NG control (Figure 9).
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Figure 9. The combination effect of Metformin (MET) and N-acetylcysteine (NAC) on high
glucose-induced casp se 3/7 activity. H9c2 cardiomyobl sts were cultured in high glucose (HG; 33 mM)
for 24 h. Thereafter, cells were treated with NAC (1 mM), metfo min (MET) (1 µM) and a combinati n
of MET+NAC. Ce ls treated with normal glucose (NG) served as the vehicle control. Results are
expressed as the mean ± SEM of 3 independent biological experiments with each experim nt having
3 technical replicates (n = 9). Significance is depicted as *** p ≤ 0.001 versus NG control, ## p ≤ 0.01
versus HG control.
3.10. Gene and Protein Expression
3.10.1. The effect of MET and NAC on phosphorylated 5’ AMP-activated protein kinase (AMPK) and
nuclear factor-kappa B phosphorylation (p-NF-kB) expression
The major kinase that plays a role in energy homeostasis is 5’ AMP-activated protein kinase
(AMPK), whilst NF-kB, a transcription factor, regulates the expression of genes involved in inflammation
in response to increased glucose levels. The expression of p-AMPK(Thr172) in H9c2 cardiomyoblasts
was significantly diminished following HG exposure when compared to the NG control (p < 0.001).
H9c2 cardiomyoblasts exposed to MET (p < 0.001) and the combination of MET+NAC (p < 0.001) were
able to significantly upregulate the expression of p-AMPK(Thr172). The combination treatment was
similar to MET treatment only (Figure 10A) but induced significantly higher levels when compared to
NAC alone (p < 0.05). HG exposed H9c2 cells presented with a significant increase in p-NF-kB(Ser536)
expression when compared to cells cultured in NG (p < 0.001). NAC (p < 0.001), MET (p < 0.001), as well
as the combination of MET+NAC (p < 0.001) were able to significantly attenuate the phosphorylation of
NF-kB(Ser536). Interestingly, NAC treatment only was better at attenuating p-NF-kB protein expression
compared to either MET or the combination of MET+NAC treatment (p < 0.05 against Met+NAC;
Figure 10B).
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resistance. A significant increase in IRS-1(Ser307) phosphorylation was observed in H9c2 
cardiomyoblasts exposed to HG when compared to the NG control (p < 0.001). Treatment with NAC 
(p < 0.01), MET (p < 0.001) and the combination of MET+NAC (p < 0.05) were able to alleviate this 
effect (Figure 11B). 
Phosphorylated protein kinase B (pAKT) signalling plays a central role in insulin-stimulated 
GLUT4 expression. In the present study, H9c2 cardiomyoblasts cultured in HG presented with a 
significant decrease in the expression of AKT when compared to the NG control (p < 0.001). 
Interestingly, MET, NAC showed an increasing trend, whereas the combination (MET+NAC) 
treatment significantly (p < 0.001) increased AKT expression (Figure 11C). Similarly, this study 
showed that GLUT4 expression, which is a major transporter of glucose in the heart, was affected by 
HG exposure. HG resulted in a significant decrease in GLUT4 expression when compared to cells 
Figure 10. The combination effect of Metformin (MET) and N-acetylcysteine (NAC) on 5’ AMP-activated
protein kinase phosphorylation at threonine 172 (p-AMPKThr172) and nuclear factor-kappa B
phosphorylation at serine 536 (p-NF-kB (Ser536)). Protein expression of (A) p-AMPK(Thr172) and
(B) p-NF-kB (Ser536) on H9c2 cardiomyoblasts cultured in high glucose (HG; 33 mM) for 24 h. Thereafter,
cells were treated with NAC (1 mM), metformin (MET) (1 µM) and a combination of MET+NAC. Cells
treated with normal glucose (NG) served as the vehicle control. Results are expressed as the mean
± SEM of 3 independent biological experiments with each experiment having 3 technical replicates
(n = 9). Significance is depicted as *** p ≤ 0.001 versus NG control, ### p ≤ 0.001 versus HG control,
† p ≤ versus MET and ‡ p ≤ 0.05 versus NAC.
3.10.2. The effect of MET and NAC to increased glucose uptake, through the inhibition of
phosphorylated protein kinase C (PKC(Ser660))/insulin receptor substrate-1 (IRS-1(Ser307)) inhibition
Increased serine phosphorylation of protein kinase (p-PKC(Ser660)) has been linked with insulin
resistance. H9c2 cardiomyoblasts cultured in HG significantly increased the expression of p-PKC(Ser660)
when compared to the NG control (p < 0.001). Treatment with NAC (p < 0.01), MET (p < 0.001) as
well as MET+NAC (p < 0.001) significantly mitigated the phosphorylation of PKC when compared
to the HG control (Figure 11A). Furthermore, serine phosphorylation of insulin receptor substrate-1
(p-IRS-1(Ser307)) inhibi s insulin signalling which cont ibutes to pe ipheral insulin resistance. A
ignificant increase in IRS-1(Ser307) phosphorylation was observed in H9c2 cardiomyob ast exposed
to HG when compared to the NG control (p < 0.001). Treatment wi h NAC (p < 0.01), MET (p < 0.001)
and the c mbination of MET+NAC (p < 0.05) were able to alleviate this effect (Figure 11B).
Phosphorylated protein kinase B (pAKT) signalling plays a central role in insulin-stimulated
GLUT4 expression. In the present study, H9c2 cardiomyoblasts cultured in HG presented with a
significant decrease in the expression of AKT when compared to the NG control (p < 0.001). Interestingly,
MET, NAC showed an increasing trend, whereas the combination (MET+NAC) treatment significantly
(p < 0.05) increased AKT expression (Figure 11C). Similarly, this study showed that GLUT4 expression,
which is a major transporter of glucose in the heart, was affected by HG exposure. HG resulted in a
significant decrease in GLUT4 expression when compared to cells cultured in NG (p < 0.001). However,
this reduction was significantly reversed following treatment with NAC (p < 0.001), MET (p < 0.001)
and that of MET+NAC (p < 0.001) when compared to the HG control (Figure 11D).
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4. Discussion 
Due to an ageing population and amplified diabesity epidemic, HF is increasing worldwide [24]. 
Current consensus is that chronic hyperglycaemia and hyperlipidaemia are the main initiators of 
Figure 11. The combination effect of Metformin (MET) and N-acetylcysteine (NAC) on selected targets
in the insulin signalli g pathway. Protein expression of (A) protein kinase C phosph rylation at
Serine 660 (p-PKC(Ser660)), (B) insulin receptor substrate-1 at Serine 307 (p-IRS-1(Ser307)), (C) protein
kinase B phosphorylation at Serine 473 (p-AKT(Ser473)) and (D) glucose transporter 4 (GLUT4) protein
expression of H9c2 cardiomyoblasts cultured in high glucose (HG; 33 mM) for 24 h. Thereafter, cells
were treated with NAC (1 mM), metformin (MET) (1 µM) and a combination of MET+NAC. Cells
treated with normal glucose (NG) served as the vehicle control. Results are expressed as the mean
± SEM of 3 Independent biological experiments with each experiment having 3 technical replicates
(n = 9). Significance is depicted as * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 versus NG control, # p ≤ 0.05,
## p ≤ 0.01, ### p ≤ 0.01 versus HG control, and ‡‡ p ≤ 0.01 versus MET.
4. Discussion
D e to an ageing population and amplified diabesity epidemic, HF is increasing worldwide [24].
Current consensus is that chronic hyperglycaemia and hyperlipidaemia are the main initiators of
augmented oxidative stress. This imbalance between the production of free radicals and the inability
of the body’s endogenous antioxidant system to counteract or detoxify reactive products is known to
increase the risk of premature HF [25–27].
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To date, scientific evidence has shown that current glucose-lowering drugs, such as MET, are able
to protect the myocardium against augmented oxidative stress [28–31]. However, the ability of MET to
protect the myocardium may be reduced over time, emphasising the need to incorporate alternative
therapies as an adjunct to improve the endogenous antioxidant status of the diabetic heart. As such,
studies have presented data reporting on the preventive properties of NAC in hyperglycaemia-induced
oxidative stress [11,32–35]. Dludla (2018) performed a systematic review confirming the ameliorative
properties of NAC and highlighted that there is a scarcity of data reporting on the comparative effect
of NAC with common glucose-lowering therapies on the diabetic myocardium [11]. Therefore, this
study set out to investigate if the combined use of MET and NAC is better than the use of MET alone
to protect the diabetic myocardium against aberrant hyperglycaemia-induced oxidative stress and cell
apoptosis induced by the hyperglycaemic state.
In a systematic review performed by Kajbaf and colleagues (2016), the authors reported that MET
and NAC therapy are beneficial within a disease state [29]. The authors further elaborated on the
plasma concentrations of MET and NAC, further stating that for MET and NAC to have therapeutic
effects, MET plasma concentrations must be in the range of 0.129-90 mg/L, while that of NAC equal
0.02 mM. The latter can be used to guide in vivo dose experiments. Unfortunately, there is no practical
guidelines for dose translation experiments from human to in vitro dose and as such, the selected
doses for NAC and MET were based on previous findings from our group [7,19,20]. Therefore, in this
study H9c2 cells were exposed to 1 µM MET, a clinically relevant dose that closely mimics metformin
serum levels, while NAC was used at 1 mM, an accomplished in vitro experimental dose. In this
context, H9c2 cells exposed to HG were either treated alone or in combination with MET and NAC, as
previously reported [7]. Consequently, experimental exposure of cardiomyocytes to HG increased
oxidative stress as it could be observed with a 1.5-fold increased DCFH-DA level, while SOD and GSH
levels were significantly decreased, suggesting a depletion of intracellular antioxidative mechanisms.
This study presented data on NAC, MET and the combination of MET+NAC’s ability to reverse
accelerated oxidative stress which is known to induce tissue damage. Findings from this study further
support published data confirming that administration of NAC replenishes GSH and SOD levels, while
reducing oxidative stress markers in the myocardium of infarcted rat hearts [35–37]. N-acetylcysteine
is a precursor to the amino acid L-cysteine and consequently the antioxidant GSH. Therefore, we
were expecting to detect an enhanced effect with the amalgamation of MET and NAC, however no
significant additive or synergistic effects were observed. In saying that, Dludla (2018) reported that
the effect of NAC to display health promoting properties could possibly be dependent on the dose
selection [11] and therefore, we speculate that the correct combination of mixing the doses of MET
and NAC might possibly be better at replenishing intracellular GSH. On the other hand, the results
suggested that markers of late stage tissue damage, such as the end products of lipid peroxidation
(TBARS) and late stage apoptosis as indicated by caspase 3/7 activation and DNA damage (Tunel
assay), were only partially reversed by the treatments. This damage was likely incurred during the
initial HG treatment and it could be speculated that MET and NAC treatment during this initial period
of HG exposure may be able to provide more comprehensive protection of these cells.
Apart from abnormal redox cycling induced by chronic glucose exposure, excessive amounts
of ROS will interfere with cellular processes and oxidatively degrade membrane lipids in a process
called lipid peroxidation. As such, lipid peroxidation can be seen as one of the major mechanisms
associated with accelerated myocardial damage in the diabetic state. In a study published in 2013
by Basha and Priscilla, the authors showed that NAC pre-treatment at a dose of 10 mg/kg daily for
14 days in rats displayed robust antioxidant properties against isoproterenol induced myocardial lipid
peroxidation and mitochondrial dysfunction similarly, while modulating calcium handling during
ischemic reperfusion injury [38]. In another study, Nagoor and Meeran (2011) found that treatment
of rats with 10 mg/kg, instead of 5 mg/kg, of NAC was more effective in reducing lipid peroxidation
in isoproterenol-induced myocardial infarcted rats [33]. In the current study we showed that NAC
treatment was able to ameliorate lipid peroxidation with a similar effect to that of the combined
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treatment of MET and NAC. Interestingly, the observed effect, though statistically significant, was once
again not additive or synergistic and we speculated that a higher dose of NAC might have produced a
more marked effect.
Apart from increased oxidative stress and lipid peroxidation, intracellular lipid accumulation
plays an important role in the development of cardiac dysfunction [8]. The heart uses larger amounts
of fatty acids as an energy source (70%) in order to maintain the physiological balance between
lipid uptake and oxidation [8]. During the diabetic state, these carefully controlled processes are
altered, resulting in the accumulation of lipid, while using exclusively fatty acid oxidation as an energy
source [7]. This will then lead to a chronic altered state with decreased ATP production and energy
depletion of the failing heart. In our previous study, we confirmed such a phenomenon, showing
how increased fatty acid utilisation after chronic glucose exposure decreased metabolic activity [7].
Consistent with previously reported data on myocardial energy efficiency, our results showed that
treatment of H9c2 cells with HG induced a significant decrease in metabolic content and GU, while
increasing lipid accumulation. It is acknowledged that MET inhibits complex 1, thereby preventing
mitochondrial ATP production. However, this effect can be reversed by a key kinase, AMPK, a master
energy regulator that is also known to modulate lipid metabolism. In a disease state, during reduced
ATP levels, AMPK is phosphorylated at Thr172, which results in the activation of AMPK and in
turn inhibits anabolic processes while catabolic processes and ATP production is increased [39]. The
latter finding was supported by Hu (2016) and in the current study, we showed that MET enhanced
phosphorylation levels of AMPK in H9c2 cells which resulted in the alteration of cellular redox status
and the reversal of HG-induced inhibition of ATP content [40]. Furthermore, Hu (2016) continued and
showed that MET was able to activate AMPK in H9c2 cells at 1 mM, 5 mM and 10 mM. However, in this
study we showed that MET at a concentration as low as 1 µM was able to increase phosphorylation of
AMPK which correlated to an increased in ATP production in cultured cardiomyocytes. This study was
also the first to show that the combinatory use of MET plus NAC was significantly more effective than
the use of NAC alone, and showed a trend towards increasing energy efficiency and GU compared to
MET alone. This effect of the combination drugs was confirmed by the reduction of lipid accumulation,
which was similar to that of MET treatment.
It is further acknowledged that glucose homeostasis is maintained by insulin which facilitates the
uptake of glucose into peripheral tissue via the GLUT4 transporter. Improved glucose disposal accounts
for the redistribution of GLUT4 to the plasma membrane and subsequent regulation and maintenance of
glucose homeostasis. Mechanistically, it is known that the NF-kB(Ser536)/p-PKC(Ser660)/p-IRS(Ser307)
signalling pathway plays a major role in regulating glucose homeostasis in cardiac cells, while
p-AMPK/p-AKT signalling ensures cellular homeostasis through increased GLUT4 uptake (41). As such,
increased p-PKC(Ser660)/p-IRS(Ser307) signalling has been linked to augmented lipid accumulation
and decreased GU in the diabetic heart [41]. Furthermore, activated p-AMPK and p-AKT are key
mediators in salvaging glucose-induced cardiac injury in adult cardiomyocytes [41]. Our findings
showed that the combination of MET and NAC was able to enhance GU by reversing the inhibitory effect
that p-NF-kB(Ser536)/p-PKC(Ser660)/p-IRS(Ser307) signalling has on p-AMPK(Thr172)/p-AKT(Ser473)
ability to increase GU. Interestingly, we found that NAC was able to mediate the observed effect
through activation and phosphorylation of p-AKT. Next, we aimed to investigate the effect of MET
and NAC on preventing cellular apoptosis. Results from this study were the first to show that the
combination of MET and NAC showed improved activity in preventing DNA breaks. NAC treatment
had a comparable effect in preventing cardiac apoptosis as compared to the use of MET alone, once
again confirming NACs ability to decrease hyperglycaemia-induced cellular apoptosis.
5. Conclusions
The findings from this study offer plausible validation that NAC was able to attenuate high
glucose-induced oxidative stress, lipid peroxidation and subsequent myocardial apoptosis in H9c2
cardiomyoblasts. However, though effective, the combination of MET and NAC did not diminish
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the protective effects of the MET treatment alone, which makes the combination of MET and NAC a
promising candidate to further investigate their potential to protect the diabetic heart from developing
cardiomyopathy. In addition, based on the results obtained we speculate that the combinatory effect of
NAC and MET might be more beneficial in improving glucose uptake and increasing the endogenous
antioxidant activity. If this holds true then such combination therapy would be worth pursuing,
however, this requires further investigation. The authors acknowledge the following limitations to the
study; (1) that the efficacy of the combined treatment was only tested in a single H9c2 cardiomyoblast
model and (2) lipid toxicity is a phenomenon that occurs over a period of time and that the present
study only investigated a single episode of hyperglycaemia. As such, future studies would be needed
to confirm such findings on an in vivo rat model.
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